SCHEMBL94500

SCHEMBL94500

CCNc1nncs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12571300 0.79 TSHR (0.59)
SCHEMBL7539726 0.78 TSHR (0.57)
SCHEMBL12763781 0.77 CYP1A2 (0.61)
SCHEMBL6698873 0.75 CYP1A2 (0.59)
SCHEMBL84691 0.73
SCHEMBL19997205 0.71 CYP1A2 (0.48)
SCHEMBL10089552 0.69
SCHEMBL11583116 0.67 CA2 (0.57)
SCHEMBL2915082 0.65 CA1 (0.66)
SCHEMBL14401558 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0641193-A4 CHEMOTHERAPEUTIC DRUG COMBINATIONS. MARTIN DANIEL S (US) 1995-09-06 EP claimed
EP-0641193-A1 CHEMOTHERAPEUTIC DRUG COMBINATIONS PRO-NEURON, INC. (US) 1995-03-08 EP claimed
WO-1993023014-A1 CHEMOTHERAPEUTIC DRUG COMBINATIONS MARTIN DANIEL S (US) 1993-11-25 WO claimed
CN-109071526-B Acid addition salts of piperazine derivatives 阿森纽荣股份公司 2023-02-28 CN disclosed
WO-2022035997-A1 IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS AVILAR THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
CN-109908124-A Utilize the method for hyperuricemia in Halofenate or HALOFENIC ACID and the second uric acid depressant treatment patient with gout 西玛贝医药公司 2019-06-21 CN disclosed
US-10137112-B2 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent CYMABAY THERAPEUTICS, INC. (US) 2018-11-27 US disclosed
US-20180214420-A1 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent CYMABAY THERAPEUTICS, INC. (US) 2018-08-02 US disclosed
US-9801860-B2 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent CYMABAY THERAPEUTICS, INC. (US) 2017-10-31 US disclosed
US-20160271111-A1 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent CYMABAY THERAPEUTICS, INC. (US) 2016-09-22 US disclosed
US-9439891-B2 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent CYMABAY THERAPEUTICS, INC. (US) 2016-09-13 US disclosed
EP-1878812-A1 COPPER SURFACE TREATMENT METHOD AND COPPER HITACHI CHEMICAL COMPANY, LTD. (JP) 2008-01-16 EP disclosed
WO-2006135602-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS UNIVERSITY OF ROCHESTER (US) 2006-12-21 WO disclosed
US-20040082576-A1 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-04-29 US disclosed
EP-0357783-B1 SECONDARY NON-LINEAR OPTICAL MATERIAL AND NON-LINEAR OPTICAL ELEMENT PREPARED THEREFROM SUMITOMO ELECTRIC INDUSTRIES (JP) 1994-10-26 EP disclosed
WO-1993023014-A1 CHEMOTHERAPEUTIC DRUG COMBINATIONS MARTIN DANIEL S (US) 1993-11-25 WO disclosed
EP-0357783-A1 SECONDARY NON-LINEAR OPTICAL MATERIAL AND NON-LINEAR OPTICAL ELEMENT PREPARED THEREFROM SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) 1990-03-14 EP disclosed
US-4357396-A MIRRORS PPG INDUSTRIES, INC. (US) 1982-11-02 US disclosed
US-4350804-A Curable compositions comprising an azole-functional resin and a metal-ligand complex PPG INDUSTRIES, INC. (US) 1982-09-21 US disclosed
US-3949082-A Thiadiazoles as anti-inflammatory agents MERCK & CO., INC. (US) 1976-04-06 US disclosed